FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366236988> ?p ?o ?g. }

• W4366236988 abstract "Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment. Current environmental and genetic factors could only explain part of the variability in clopidogrel efficacy. Human platelets harbor abundant miRNAs which might affect clopidogrel efficacy by regulating the expression of key proteins in the clopidogrel antiplatelet signaling pathway. This study aimed to investigate the association between platelet miRNA levels and clopidogrel efficacy. Here we recruited 508 CAD patients who underwent clopidogrel antiplatelet therapy and determined the platelet reactivity index (PRI) to evaluate antiplatelet reactivity responses to clopidogrel. Subsequently, 22 patients with extreme clopidogrel response were selected for platelet small RNA sequencing. Another 41 CAD patients taking clopidogrel were collected to verify the differentially expressed candidate miRNAs. We found the metabolic types of the CYP2C19 enzyme (based on CYP2C19 * 2 and * 3 polymorphisms) could significantly affect the PRI of CAD patients with or without percutaneous coronary intervention (PCI) in Chinese. A total of 43 miRNAs were differentially expressed in the platelets from the 22 extreme clopidogrel response samples, and 109 miRNAs were differentially expressed in the 13 CYP2C19 extensive metabolizers with extreme clopidogrel response. Platelet miR-199a-5p levels were correlated negatively with PRI after clopidogrel therapy. Studies in cultured cells revealed that miR-199a-5p inhibited the expression of VASP, a key effector protein downstream of the P2Y12 receptor. In conclusion, we found the expression of VASP could be inhibited by miR-199a-5p, and decreased platelet miR-199a-5p was associated with high on-clopidogrel platelet reactivity in CAD patients.What is the context?● Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment.● Current environmental and genetic factors could only explain part of the variability in clopidogrel efficacy.● Human platelets harbor abundant miRNAs which might affect clopidogrel efficacy by regulating the expression of key proteins in the clopidogrel antiplatelet signaling pathway.What is new?● We found that decreased platelet miR-199a-5p level was associated with high on-clopidogrel platelet reactivity.● Overexpression of miR-199a-5p significantly down-regulated the expression of VASP protein in cultured cells.What is the impact?● The current study provided new insights into the exploration of interindividual variability in clopidogrel response from the perspective of miR-199a-5p and VASP interaction." @default.
• W4366236988 created "2023-04-20" @default.
• W4366236988 creator A5000359400 @default.
• W4366236988 creator A5003074405 @default.
• W4366236988 creator A5017856049 @default.
• W4366236988 creator A5027931376 @default.
• W4366236988 creator A5034237051 @default.
• W4366236988 creator A5035886812 @default.
• W4366236988 creator A5045206097 @default.
• W4366236988 creator A5053087783 @default.
• W4366236988 creator A5079796683 @default.
• W4366236988 creator A5091070290 @default.
• W4366236988 date "2023-04-18" @default.
• W4366236988 modified "2023-10-17" @default.
• W4366236988 title "Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease" @default.
• W4366236988 cites W1409766979 @default.
• W4366236988 cites W1553345686 @default.
• W4366236988 cites W168371622 @default.
• W4366236988 cites W1970714992 @default.
• W4366236988 cites W1978208518 @default.
• W4366236988 cites W1990018236 @default.
• W4366236988 cites W1990228066 @default.
• W4366236988 cites W1996322545 @default.
• W4366236988 cites W2007602661 @default.
• W4366236988 cites W2012343501 @default.
• W4366236988 cites W2016953051 @default.
• W4366236988 cites W2018234502 @default.
• W4366236988 cites W2039881470 @default.
• W4366236988 cites W2041694866 @default.
• W4366236988 cites W2044305934 @default.
• W4366236988 cites W2057506947 @default.
• W4366236988 cites W2065566217 @default.
• W4366236988 cites W2068252527 @default.
• W4366236988 cites W2081548185 @default.
• W4366236988 cites W2082957297 @default.
• W4366236988 cites W2084673482 @default.
• W4366236988 cites W2090989590 @default.
• W4366236988 cites W2107085058 @default.
• W4366236988 cites W2110897264 @default.
• W4366236988 cites W2119951798 @default.
• W4366236988 cites W2154940301 @default.
• W4366236988 cites W2157212226 @default.
• W4366236988 cites W2157454492 @default.
• W4366236988 cites W2161785946 @default.
• W4366236988 cites W2162916349 @default.
• W4366236988 cites W2165938620 @default.
• W4366236988 cites W2193219814 @default.
• W4366236988 cites W2264995213 @default.
• W4366236988 cites W2342257706 @default.
• W4366236988 cites W2460422691 @default.
• W4366236988 cites W2553125603 @default.
• W4366236988 cites W2555189121 @default.
• W4366236988 cites W2560198845 @default.
• W4366236988 cites W2567280222 @default.
• W4366236988 cites W2734482885 @default.
• W4366236988 cites W2791320534 @default.
• W4366236988 cites W2885388246 @default.
• W4366236988 cites W2891072599 @default.
• W4366236988 cites W2990953346 @default.
• W4366236988 cites W3003299879 @default.
• W4366236988 cites W3094195230 @default.
• W4366236988 cites W4200013532 @default.
• W4366236988 cites W4210566043 @default.
• W4366236988 doi "https://doi.org/10.1080/09537104.2023.2200860" @default.
• W4366236988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37070954" @default.
• W4366236988 hasPublicationYear "2023" @default.
• W4366236988 type Work @default.
• W4366236988 citedByCount "0" @default.
• W4366236988 crossrefType "journal-article" @default.
• W4366236988 hasAuthorship W4366236988A5000359400 @default.
• W4366236988 hasAuthorship W4366236988A5003074405 @default.
• W4366236988 hasAuthorship W4366236988A5017856049 @default.
• W4366236988 hasAuthorship W4366236988A5027931376 @default.
• W4366236988 hasAuthorship W4366236988A5034237051 @default.
• W4366236988 hasAuthorship W4366236988A5035886812 @default.
• W4366236988 hasAuthorship W4366236988A5045206097 @default.
• W4366236988 hasAuthorship W4366236988A5053087783 @default.
• W4366236988 hasAuthorship W4366236988A5079796683 @default.
• W4366236988 hasAuthorship W4366236988A5091070290 @default.
• W4366236988 hasBestOaLocation W43662369881 @default.
• W4366236988 hasConcept C126322002 @default.
• W4366236988 hasConcept C140840227 @default.
• W4366236988 hasConcept C164705383 @default.
• W4366236988 hasConcept C2777628954 @default.
• W4366236988 hasConcept C2777698277 @default.
• W4366236988 hasConcept C2777849778 @default.
• W4366236988 hasConcept C2778213512 @default.
• W4366236988 hasConcept C2780400711 @default.
• W4366236988 hasConcept C3018697912 @default.
• W4366236988 hasConcept C49059817 @default.
• W4366236988 hasConcept C500558357 @default.
• W4366236988 hasConcept C526171541 @default.
• W4366236988 hasConcept C62231903 @default.
• W4366236988 hasConcept C71924100 @default.
• W4366236988 hasConcept C89560881 @default.
• W4366236988 hasConcept C98274493 @default.
• W4366236988 hasConceptScore W4366236988C126322002 @default.
• W4366236988 hasConceptScore W4366236988C140840227 @default.
• W4366236988 hasConceptScore W4366236988C164705383 @default.
• W4366236988 hasConceptScore W4366236988C2777628954 @default.

• next